

- 119 -

## WHAT IS CLAIMED IS:

1. A compound of Formula 1 having the structure:

$$G_1$$
 $G_2$ 
 $R_1$ 
 $C \not\equiv N$ 
 $R_4$ 
 $R_4$ 

wherein:

5


10

15

20

25

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono- di-, or tra-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalky 1 of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkerloylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalky of 3-8 carbon atoms, anninoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, and benzoylamino;



Z is -NH-, -O-, -S-, or -NR-;

R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 ¢arbon atoms;

G<sub>1</sub>, G<sub>2</sub>, R<sub>1</sub>, and R<sub>4</sub> are each, independently, hydrøgen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms. alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benz/yl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,

20

5

10

15

$$R_7$$
- $(C(R_6)_2)_p$ - $N$ - $(C(R_6)_2)_k$ - $Y$ - $R_8$  $R_9$ - $CH$ - $M$ - $(C(R_6)_2)_k$ - $Y$ - $(C(R_6)_2)_p$ 

 $R_7$ -( $C(R_6)_2)_g$ -Y- ,  $R_7$ -( $C(R_6)_2)_p$ -M-( $C(R_6)_2)_k$ -Y- , or Het-( $C(R_6)_2)_q$ -W-( $C(R_6)_2)_k$ -Y- with the proviso that either  $G_1$  or  $G_2$  or both  $G_1$  and  $G_2$  must be a radical selected from the group

10

20

$$R_{7}\text{-}(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{k}\text{-}Y - R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{k}\text{-}Y - R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{k}\text{-}Y - R_{7}\text{-}(C(R_{6})_{2})_{p}\text{-}M - (C(R_{6})_{2})_{p}\text{-}M - (C(R_{6})_{2})_{k}\text{-}Y - R_{7}\text{-}(C(R_{6})_{2})_{p}\text{-}M - (C(R_{6})_{2})_{p}\text{-}M - (C(R_{6$$

Y is a divalent radical selected from the group consisting of

$$-(CH_2)_a$$
 ,  $-O$  , and  $-N$ 


 $R_7$  is  $-NR_6R_6$ , -J,  $-OR_6$ ,  $-N(R_6)_3$ , of  $NR_6(OR_6)$ ;

R'7 is -NR<sub>6</sub>(OR<sub>6</sub>), -N(R<sub>6</sub>)<sub>3</sub>, alkenoxy of 1-6 carbon atoms, alkynoxy of 1-6 carbon atoms, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, N-alkyl-N-alkynylamino of 4 to 12 carbon atoms, N-alkenyl-N-alkynylamino of 4 to 12 carbon atoms, or N,N-dialkynylamino of 6-12 carbon atoms with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

M is  $>NR_6$ , -O-, >N- $(C(R_6)_2)_p/NR_6R_6$ , or >N- $(C(R_6)_2)_p$ - $OR_6$ ;

15 W is  $>NR_6$ , -O- or is a bond;

Het is a heterocycle selected from the group consisting of morpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane,



- 122 -

wherein the heterocycle is optionally mono- or di-substituted on carbon or nitrogen with  $R_6$ , optionally mono- or di-substituted on carbon with hydroxy,  $-N(R_6)_{2,}$  or  $-OR_6$ , optionally mono or di-substituted on carbon with the mono-valent radicals  $-(C(R_6)_2)_SOR_6$  or  $-(C(R_6)_2)_SN(R_6)_2$ , or optionally mono or di-substituted on a saturated carbon with divalent radicals -O- or  $-O(C(R_6)_2)_SO$ -;

R6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;

R2, is selected from the group/consisting of

20

10

$$R_3$$
 $R_3$ 
 $R_3$ 

ogasezo..ogetos

eptember 1999 ZED124:0CO:ASM 33,451 PATENT

124 -

R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-

6 carbon atoms, phenyl, carboalkyl of/2-7 carbon atoms,

$$R_{7}\text{-}(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r}\text{-}$$


$$R_{7}\text{-}(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r}\text{-}$$

$$R_{7}\text{-}(C(R_{6})_{2})_{s} - R_{7}\text{-}(C(R_{6})_{2})_{p}\text{-}M - (C(R_{6})_{2})_{r}\text{-}$$

$$R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} , or Het\text{-}(C(R_{6})_{2})_{q}\text{-}W\text{-}(C(R_{6})_{2})_{r}\text{-}$$

with the proviso that at least one of the R3 groups is selected from the group

10



125 -

$$R_{7}\text{-}(C(R_{6})_{2})_{p} - N \qquad N - (C(R_{6})_{2})_{r}\text{-} \\ (C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r}\text{-} \\ R'_{7}\text{-}(C(R_{6})_{2})_{s}\text{-} \qquad R_{7}\text{-}(C(R_{6})_{2})_{p}\text{-} M - (C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{q}\text{-}W\text{-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{q}\text{-}W\text{-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{q}\text{-}W\text{-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{q}\text{-}W\text{-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{q}\text{-}W\text{-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{q}\text{-}W\text{-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{r}\text{-} \\ R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad , \text{ or } \text{Het-}(C(R_{6})_{2})_{r}\text{-}$$

R5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

$$R_{7}\text{-}(C(R_{6})_{2})_{p} - N \qquad N - (C(R_{6})_{2})_{r}\text{-}$$

$$(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r}\text{-}$$


$$R_{7}\text{-}(C(R_{6})_{2})_{s}\text{-} \qquad R_{7}\text{-}(C(R_{6})_{2})_{p}\text{-}M - (C(R_{6})_{2})_{r}\text{-}$$

$$R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} \qquad A - (C(R_{6})_{2})_{q}\text{-}W - (C(R_{6})_{2})_{r}\text{-}$$

R<sub>8</sub>, and R<sub>9</sub> are each, independently,  $-\sqrt{C(R_6)_2}$ <sub>r</sub>NR<sub>6</sub>R<sub>6</sub>, or  $-(C(R_6)_2)$ <sub>r</sub> OR<sub>6</sub>;

J is independently hydrogen, chlorine, fluorine, or bromine; Q is alkyl of 1-6 carbon atoms or hydrogen;

20 s = 1-6; u = 0-4 and v = 0-4, wherein the sum of u+v is 2-4;



or a pharmaceutically acceptable salt thereof, provided that

when R6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

and further provided that

when Y is -NR6- and R7 is -NR6R6,  $N(R_6)_3$ , or -NR6(OR6), then g = 2-6;

when M is -O- and R7 is -OR6, then p = 1-4;

when Y is -NR6-, then k = 2-4;

when Y is -O- and M or W is -O-, then k = 1-4

when W is not a bond with Het bonded through a nitrogen atom, then q = 2-4 and when W is a bond with Het bonded through a nitrogen atom and Y is -O-

or -NR<sub>6</sub>-, then k = 2-4.

- 15 2. The compound according to claim 1 wherein Z is -NH- and n = 0 or a pharmaceutically acceptable salt thereof.
  - 3. The compound according to claim 2 wherein X is optionally substituted phenyl or a pharmaceutically acceptable salt thereof.

20


5

- 4. The compound according to claim 3 wherein  $R_1$  and  $R_4$  are hydrogen or a pharmaceutically acceptable salt thereof.
- 5. The compound according to claim 1, which is:

25

a) 1-Methyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;

30



127 -

- b) N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolinyl]-4-(N-allyl-N-methylamino)-2-butynamide or a pharmaceutically acceptable salt thereof;
- c) N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolinyl]-4-(N-methoxyethyl-N-methylamino)-2-butynamide or a pharmaceutically acceptable salt thereof;
  - d) N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolinyl]-4-(bis-(2-methoxyethyl)amino)-2-butynamide or a pharmaceutically acceptable salt thereof;

e) 4-Methoxymethoxy-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;


f) 4-(4-Chloro-2-fluoro-phenylamino)-6-methoxy-7-(2-pyridin-4-yl-ethoxy)quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;

- g) 4-(2-Methoxy-ethoxy)-but-2-ynoic acid [4-(3-bromo-phenylamino)-3- cyano-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- 20 h) 4-((2S)-2-Methoxymethylpyrrolidin-1-yl)but-2-ynoic Acid [4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]amide or a pharmaceutically acceptable salt thereof;
- i) 4-(1,4-Dioxa-8-azaspiro[4,5]dec-8-yl)but-2-ynoic Acid [4-(3 25 Bromophenylamino)-3-cyanoquinolin-6-yl] amide or a pharmaceutically acceptable salt thereof;
  - j) 4-(3-Bromo-phenylamino)-6-(2-ethoxy-3,4-dioxo-cyclobut-1-enylamino)-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;

- k) 4-[(2-Methoxy-ethyl)-methyl-amino]-but-2-enoic acid [4-(3-chloro-4- fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- 5 l) (S)-4-(2-Methoxymethyl-pyrrolidin-1-yl)-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide dihydrochloride or a pharmaceutically acceptable salt thereof;
- m) 4-(3-Hydroxymethyl-piperidin-1-yl)-but-2-enoic acid [4-(3-chloro-4- fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- n) 4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-but-2-enoic acid [4-(3- chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
  - o) 4-(2-Hydroxymethyl-piperidin-1-yl)-but-2-enoic acid [4-(3-chloro-4- fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
  - p) 4-Bromo-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- q) 4-(3-hydroxy-4-methyl-phenylamino)-6-methoxy-7-(3-pyridin-4-yl-propoxy)quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
  - r) 4-Diallylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3cyano-7-methoxy- quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;

123





- 129 -

- s) 4-[Bis-(2-methoxy-ethyl)-amino]- but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)- 3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- 5 t) 4-([1,3]Dioxolan-2-ylmethyl-methyl-amino)-but-2-enoic acid 3-cyano-7-methoxy -quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- u) 4-[Bis-(2-hydroxy-ethyl)-amino]-but-2-enoic acid [4-(3-chloro-4-fluoro-10 phenylamino)-3-cyano-7-methoxy- quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- v) 4-Thiomorpholin-4-yl-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
  - w) 4-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy- quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;

x) 4-(1,4,7-Trioxa-10-aza-cyclododec-10-yl)-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy- quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;

- 25 y) 4-(Methoxy-methyl-amino)-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- 4-(4-Hydroxy-piperidin-1-yl)-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;

4-[1,4']Bipiperidinyl-1'-yl-but-2-enoic acid [4-(3-chloro-4-fluoroaa) phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;

5

4-Thiazolidin-3-yl-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3bb) cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof:

10

cc)

3-{3-[4-(3-Chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-ylca rbamoyl]-allyl}-4-methyl-thiazol-3-ium bromide or a pharmaceutically acceptable salt thereof;

4-(2,6-Dimethyl-piperidin-1-yl)-but-2-enoic acid [4-(3-chloro-4-fluorodd) 15 phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;

20

4-[Bis-(2-hydroxy-propyl)-amino]-but-2-enoic acid [4-(3-chloro-4-fluoroee) phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;

ff) 4-(3-Hydroxy-pyrrolidin-1-yl)-but-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;

25

4-[(2-Hydroxy-ethyl)-methyl-amino]-but-2-enoic acid [4-(3-chloro-4-fluorogg) phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof:

25


131 -

- hh) 4-(2,5-Dimethyl-pyrrolidin-1-yl)-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- 5 ii) 4-(4,4-Dihydroxy-piperidin-1-yl)-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
- jj) 4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-6-pyrrolidin-1-yl-quinoline-3 carbonitrile or a pharmaceutically acceptable salt thereof;
  - kk) 4-(3-Chloro-4-fluroanilino)-7-methoxy-6-(1H-pyrrol-1-yl)-3quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- 15 ll) 6-(1-Aziridinyl)-4-(3-chloro-4-fluoroanilino)-7-methoxy-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - mm) 4-[(2-Methoxy-ethyl)-methyl-amino]-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof;
  - nn) 4-(2,4-Dichloro-5-methoxy-phenylamino)-7-[3-(4-hydroxy-piperidin-1-yl)-propoxy]-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
  - oo) 4-(2,4-Dichloro-5-methoxy-phenylamino)-7-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propoxy}-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;

- 132 -

- pp) 4-(2-Bromo-4-chloro-phenylamino)-7-{2-[(2-hydroxy-ethyl)-methyl-amino]-ethoxy}-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- 5 qq) 4-(2,4-Dichloro-5-methoxy-phenylamino)-7-{3-[(2-hydroxy-ethyl)-methyl-amino]-propoxy}-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- rr) 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-(3-thiomorpholin-4-yl-propoxy)-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- ss) 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(2-methoxy-ethylamino)-propoxy]-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
  - tt) 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
  - uu) 4-(2,4-Dichloro-5-methoxy-phenylamino)-7-[3-(2,6-dimethyl-morpholin-4-yl)-propoxy]-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- 25 vv) 4-(2-Bromo-4-chloro-phenylamino)-7-{2-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-ethoxy}-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- ww) 4-(2-Bromo-4-chloro-phenylamino)-7-[2-(4-hydroxy-piperidin-1-yl)-ethoxy] 6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;

20




- 133 -

- xx) 4-(2-Bromo-4-chloro-phenylamino)-6-methoxy-7-(2-thiomorpholin-4-yl-ethoxy)-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- 5 yy) 4-(2,4-Dichloro-5-methoxy-phenylamino)-7-[3-(2,5-dimethyl-pyrrolidin-1-yl)-propoxy]-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- 4-(2,4-Dichloro-5-methoxy-phenylamino)-7-[3-(3-hydroxy-propylamino)propoxy]-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
  - aaa) 1-{3-[3-Cyano-4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-quinolin-7-yloxy]-propyl}-piperidine-4-carboxylic acid ethyl ester or a pharmaceutically acceptable salt thereof;
  - bbb) 7-[3-(4-acetyl-1-piperazinyl)propoxy]-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - ccc) 4-(3-chloro-4-fluoroanilino)-7-methyoxy-6(4-morpholinyl)-3quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- ddd) 7-[3-(4-Benzyl-piperazin-1-yl)-propoxy]-4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- eee) 4-(2,4-Dichloro-5-methoxy-phenylamino)-7-[3-(2-hydroxy-ethylamino)-propoxy]-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;

25

134 -


- fff) 4-(2,4-Dichloro-5-methoxy-phenylamino)-7-{3-[ethyl-(2-hydroxy-ethyl)-amino]-propoxy}-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- 5 ggg) 7-{3-[Bis-(2-methoxy-ethyl)-amino]-propoxy}-4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
- hhh) 7-{3-[Bis-(2-hydroxy-ethyl)-amino]-propoxy}-4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-quinoline-3-carbonitrile or a pharmaceutically acceptable salt thereof;
  - iii) 4-(3-chloro-4-fluoroanilino)-7-(4-morpholinyl)-6-nitro-3quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - jjj) N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-(4-morpholinyl)-6-quinolinyl]-2-butynamide or a pharmaceutically acceptable salt thereof;
- kkk) 6-amino-4-(3-chloro-4-fluoroanilino)-7-(4-morpholinyl)-3 quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - lll) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(3-{[2-(4-morpholinyl)ethyl]amino}propoxy)-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - mmm) 7-{3-[(2-anilinoethyl)amino]propoxy}-4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- nnn) N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-(4-morpholinyl)-6quinolinyl]acrylamide or a pharmaceutically acceptable salt thereof;



135 -

- ooo) 4-(3-chloro-4-fluoroanilino)-7-{4-[2-(dimethylamino)ethyl]-1-piperazinyl}-6-nitro-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- ppp) 6-amino-4-(3-chloro-4-fluoroanilino)-7-{4-[2-(dimethylamino)ethyl]-1 piperazinyl}-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- qqq) N-(4-(3-chloro-4-fluoroanilino)-3-cyano-7-{4-[2-(dimethylamino)ethyl]-1-piperazinyl}-6-quinolinyl)acrylamide or a pharmaceutically acceptable salt thereof;
  - rrr) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-({2-[4-(2-methoxyethyl)-1-piperazinyl]ethyl}amino)-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - sss) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(2H-1,2,3-triazol-2-yl)propoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- 20 ttt) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1H-1,2,3-triazol-1-yl)propoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- uuu) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(3-thienyl)-3quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - vvv) 4-[(E)-2-(2-quinolinyl)ethenyl]aniline or a pharmaceutically-acceptable salt thereof;





136 -

- www) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-{[2-(2H-1,2,3-triazol-2-yl)ethyl]amino}-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- 5 xxx) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-{[2-(1H-1,2,3-triazol-1-yl)ethyl]amino}-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- yyy) 4-(2,4-dichloro-5-methoxyanilino)-7-(3-thienyl)-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - zzz) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1H-1,2,4-triazol-1-yl)propoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - aaaa) 4-(2,4-dichloro-5-methoxyanilino)-7-[3-(1H-imidazol-1-yl)propoxy]-6-methoxy-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- bbbb) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1H-pyrazol-1-yl)propoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- cccc) N-[3-cyano-4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-quinolinyl]-N[4-(4-ethyl-1-piperazinyl)butyl]acetamide or a pharmaceutically acceptable
  salt thereof;
  - dddd) N-[3-cyano-4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-quinolinyl]-N- (3-(4-ethyl-1-piperazinyl)propyl)acetamide or a pharmaceutically acceptable salt thereof;

20

30





137 -

- eeee) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-{3-[4-(2-methoxyethyl)-1-piperazinyl]propoxy}-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- 5 ffff) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(1H-pyrrol-1-yl)-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - gggg) 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - hhhh) 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-[2-(2H-1,2,3-triazol-2-yl)ethoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- iiii) '4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1H-tetraazol-1-yl)propoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
  - jjjj) 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(2H-tetraazol-2-yl)propoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
    - kkkk) 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof;
- 25 llll) 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-[2-(2H-1,2,3-triazol-2-yl)ethoxy]-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof; or
  - mmmm) 4-(2,4-dichloro-5-methoxyanilino)-7-{3-[[2-(dimethylamino)ethyl] (methyl)amino]propoxy}-6-methoxy-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof.

6. A method of treating, inhibiting the growth of, or eradicating a neoplasm in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula 1 having the structure

$$G_1 \xrightarrow{R_1} Z = N$$

$$G_2 \xrightarrow{R_4} N$$

$$G_3 \xrightarrow{R_4} 1$$

wherein:

5


10

15

20

25

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridingl, pyrimidinyl, or phenyl ring may be optionally mono- di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl/of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of/1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalky of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, and benzoylamino;



Z is -NH-, -O-, -S-, or -NR-;

R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;

G<sub>1</sub>, G<sub>2</sub>, R<sub>1</sub>, and R<sub>4</sub> are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon/atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, traffluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, ¢arboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino / hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1/6/carbon atoms, dialkylamino of 2 to 12 N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-Ncarbon alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,

20

5

10


15

$$R_7$$
- $(C(R_6)_2)_p$   $N$ - $(C(R_6)_2)_k$ -Y-  $R_8R_9$ -CH-M- $(C(R_6)_2)_k$ -Y-  $(C(R_6)_2)_p$ 

 $R_7$ -( $C(R_6)_2$ )<sub>g</sub>-Y- ,  $R_7$ -( $C(R_6)_2$ )<sub>p</sub>-M-( $C(R_6)_2$ )<sub>k</sub>-Y- , or Het-( $C(R_6)_2$ )<sub>q</sub>-W-( $C(R_6)_2$ )<sub>k</sub>-Y- with the proviso that either  $G_1$  or  $G_2$  or both  $G_1$  and  $G_2$  must be a radical selected from the  $gr\phi up$ 

10

20



140 -

$$R_{7}\text{-}(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{k}\text{-}Y - R_{8}R_{9}\text{-}CH - M - (C(R_{6})_{2})_{k}\text{-}Y - (C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{k}\text{-}Y - R_{8}R_{9}\text{-}CH - M - (C(R_{6})_{2})_{k}\text{-}Y - (C(R_{6})_{2})_{p} - M - (C(R_{6})_{2})_{k}\text{-}Y - (C(R_{6})_{2})_{q}\text{-}W - (C(R_{6})_{2})_{k}\text{-}Y - R_{7}\text{-}(C(R_{6})_{2})_{p}\text{-}M - (C(R_{6})_{2})_{k}\text{-}Y - (C(R_{6})_{2})_{q}\text{-}W - (C(R_{6})_{2})_{q}\text{-}W - (C(R_{6})_{2})_{k}\text{-}Y - R_{7}\text{-}(C(R_{6})_{2})_{q}\text{-}W - (C(R_{6})_{2})_{q}\text{-}W - (C(R_{6})_{2})_{q}\text{-}W$$

or R<sub>2</sub>-N-

Y is a divalent radical selected from the group consisting of

$$-(CH_2)_a$$
 ,  $-O$  , and  $-N$ 

 $R_7$  is  $-NR_6R_6$ , -J,  $-OR_6$ ,  $-N(R_6)_3$ , or  $-NR_6(\Phi R_6)$ ;

R'7 is -NR<sub>6</sub>(OR<sub>6</sub>), -N(R<sub>6</sub>)<sub>3</sub>, alkenoxy of 1-6 darbon atoms, alkynoxy of 1-6 carbon atoms, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, N-alkyl-N-alkynylamino of 4 to 12 carbon atoms, N-alkenyl-N-alkynylamino of 4 to 12 carbon atoms, or N,N-dialkynylamino of 6-12 carbon atoms with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

M is  $>NR_6$ , -O-, >N- $(C(R_6)_2)_pNR_6R_6$  or >N- $(C(R_6)_2)_p$ - $OR_6$ ;

15 W is  $>NR_6$ , -O- or is a bond;

Het is a heterocycle selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane,


tetrahydropyran, and  $\begin{pmatrix} OCH_2CH_2O)_r \\ N \\ H \end{pmatrix}$ 

wherein the heterocycle is optionally mono- or di-substituted on carbon or nitrogen with  $R_6$ , optionally mono- or di-substituted on carbon with hydroxy,  $-N(R_6)_2$ , or  $-OR_6$ , optionally mono or di-substituted on carbon with the mono-valent radicals  $-(C(R_6)_2)_sOR_6$  or  $-(C(R_6)_2)_sN(R_6)_2$ , or optionally mono or di-substituted on a saturated carbon with divalent radicals -O- or  $-O(C(R_6)_2)_sO$ -;


R6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of/1-6 carbon atoms;

R2, is selected from the group consisting of

20



$$R_3$$
 $R_3$ 
 $R_3$ 




R3 is independently hydrogen, alkyl of 1-6/carbon atoms, carboxy, carboalkoxy of 1-

5 6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

$$R_{7}-(C(R_{6})_{2})_{p}-N -(C(R_{6})_{2})_{r}-N -(C(R_{6})_{2})_{r}-N -(C(R_{6})_{2})_{p}-N -(C(R_{6})_{2})_{p}-N -(C(R_{6})_{2})_{r}-N -(C(R_{6})_{2})_{p}-M -(C(R_{6})_{2})_{r}-N -(C(R_{6})_{2})_{r}-N -(C(R_{6})_{2})_{q}-N -(C(R_{6})_{2})_{r}-N -(C(R_{6})_{2})_{q}-N -(C(R_{6})_{2})_{r}-N -(C(R_{6})_{2})_{q}-N -(C(R_{6})_{2})$$

with the proviso that at least/one of the R3 groups is selected from the group

10



144 -

$$R_{7}-(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r} - N - (C(R_{6})_{2})_{r} - N - (C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r} - N - (C(R_{6})_{2}$$

R5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

$$R_{7}-(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r} - (C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r} - (C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r} - (C(R_{$$

R<sub>8</sub>, and R<sub>9</sub> are each, independently,  $-(\cancel{r}(R_6)_2)_rNR_6R_6$ , or  $-(C(R_6)_2)_rOR_6$ ;

J is independently hydrogen, chlorine, fluorine, or bromine; Q is alkyl of 1-6 carbon atoms or hydrogen;

20 
$$s = 1-6$$
;  
  $u = 0-4$  and  $v = 0-4$ , wherein the sum of u+v is 2-4;

when R6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

and further provided that

5

10

when Y is -NR6- and R7 is  $NR_{6}$ , -N(R<sub>6</sub>)<sub>3</sub>, or -NR<sub>6</sub>(OR<sub>6</sub>), then g = 2-6;

when M is -O- and R7 is  $\sqrt{OR_6}$ , then p = 1-4;

when Y is -NR6-, then k = 2-4;

when Y is -O- and M or W is -O-, then k = 1-4

when W is not a bond with Het bonded through a nitrogen atom, then q=2-4 and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or -NR<sub>6</sub>-, then k=2-4

- 7. The method according to claim 6 wherein the neoplasm is selected from the group consisting of breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, and lung.
- 8. A method of treating, inhibiting the progression of, or eradicating polycystic
  20 kidney disease in a mammal in need thereof which comprises administering to said
  mammal an effective amount of a compound of formula 1 having the structure

$$G_1$$
 $R_1$ 
 $Z$ 
 $C \equiv N$ 
 $R_4$ 
 $R_4$ 


25 wherein:

10

15

25

30



146 -

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, for phenyl ring may be optionally mono- di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6/carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalky of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, and benzoylamino;

Z is -NH-, -O-, -S-, or -NR-;

20 R is alkyl of 1-6 carbon atoms, or carboa/kyl of 2-7 carbon atoms;

G1, G2, R1, and R4 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkenoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulphonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy,

10

15

carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,

$$R_7$$
- $(C(R_6)_2)_p$ - $N$ - $(C(R_6)_2)_k$ - $Y$ - $(C(R_6)_2)_k$ - $Y$ - $(C(R_6)_2)_p$ - $($ 

 $R_7$ -( $C(R_6)_2$ )<sub>g</sub>-Y- ,  $R_7$ -( $C(R_6)_2$ )<sub>p</sub>-M-( $C(R_6)_2$ )<sub>k</sub>-Y- , or Het-( $C(R_6)_2$ )<sub>q</sub>-W-( $C(R_6)_2$ )<sub>k</sub>-Y- with the proviso that either  $G_1$  or  $G_2$  or both  $G_1$  and  $G_2$  must be a radical selected from the group

$$R_{7}\text{-}(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{k} + N - (C(R_{6})_$$


 $R'_{7}^{-}(C(R_{6})_{2})_{g}^{-}Y^{-} , R_{7}^{-}(C(R_{6})_{2})_{p}^{-}M^{-}(C(R_{6})_{2})_{k}^{-}Y^{-} , Het^{-}(C(R_{6})_{2})_{q}^{-}W^{-}(C(R_{6})_{2})_{k}^{-}Y^{-} ,$  or  $R_{2}^{-}\stackrel{H}{N}^{-} ;$ 

Y is a divalent radical selected from the group consisting of

$$-(CH_2)_a$$
,  $-O$ , and  $-N$ - $R_6$ 

 $R_7$  is  $-NR_6R_6$ , -J,  $-OR_6$ ,  $-N(R_6)_3$ , or  $-NR_6(OR_6)$ ;

R'7 is -NR<sub>6</sub>(OR<sub>6</sub>), -N(R<sub>6</sub>)<sub>3</sub> , alkenoxy of 1-6 carbon atoms, alkynoxy of 1-6 carbon atoms, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, N-alkyl-N-alkynylamino of 4 to 12 carbon atoms, N-alkenyl-N-



alkynylamino of 4 to 12 carbon atoms, or N,N-dialkynylamino of 6-12 carbon atoms with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

M is  $>NR_6$ ,  $-O_-$ ,  $>N_-(C(R_6)_2)_pNR_6R_6$ , or  $>N_-(C(R_6)_2)_p-OR_6$ ;

W is  $>NR_6$ , -O- or is a bond;

Het is a heterocycle selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S.S-dioxide. piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane


(OCH2CH2O)r

tetrahydropyran, and

wherein the heterocycle is optionally mono- or di-substituted on carbon or nitrogen with R<sub>6</sub>, optionally mono- or di-substituted on carbon with hydroxy,  $-N(R_6)_2$ , or  $-OR_6$ , optionally mono or di-substituted on carbon with the mono-valent radicals  $-(C(R_6)_2)_SOR_6$  or  $-(C(R_6)_2)_SN(R_6)_2$ , or optionally mono or di-substituted on a saturated carbon with divalent radicals -O- or - $O(C(R_6)_2)_sO_{-};$ 

R6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-20 6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl /(2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitrol cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon 25 atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl,

15



- 149 -

thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;

R<sub>2</sub>, is selected from the group consisting of

September 1999 :D150:0CO:ASM 33,451 PATENT

150 -

$$R_3$$
 $R_3$ 
 $R_3$ 



$$R_{5}$$
  $R_{5}$   $R_{5$ 

R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-

5 6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

$$R_{7}-(C(R_{6})_{2})_{p}-N = N - (C(R_{6})_{2})_{r}-N - (C(R_{6})_{2})_{r}-N - (C(R_{6})_{2})_{p}-N - (C(R_{6})_{2})_{p}-N - (C(R_{6})_{2})_{r}-N - (C(R_{6})_{2})_{p}-N - (C(R_{6})_{2})_{r}-N - (C(R_{6})_{2})_{r}-N - (C(R_{6})_{2})_{q}-N - (C(R_{6})_{2})_{q}-N - (C(R_{6})_{2})_{r}-N - (C(R_{6})_{2})_{q}-N - (C(R_{6})_$$

with the proviso that at least one of the R3 groups is selected from the group

R5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

 $R_{7}-(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r} - (C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r} - (C(R_{6})_{2})_{s} - R_{7}-(C(R_{6})_{2})_{s} - M - (C(R_{6})_{2})_{r} - R_{8}R_{9}-CH-M-(C(R_{6})_{2})_{r} - N - (C(R_{6})_{2})_{q}-W - (C(R_{6})_{2})_{r} - M - (C(R_{6})_{2})_{r} - M - (C(R_{6})_{2})_{r} - M - (C(R_{6})_{2})_{q} - M - (C(R_{6})_{2})_{r} - M - (C(R_{6})$ 

R<sub>8</sub>, and R<sub>9</sub> are each, independently,  $-(C(R_6/2)_rNR_6R_6$ , or  $-(C(R_6)_2)_rOR_6$ ;

J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;

a = 0 or 1;

g = 1-6;

15 k = 0-4;

n is 0-1;

p = 2-4;

q=0-4;

r = 1-4;

20 s = 1-6;

u = 0-4 and v = 0-4, wherein the sum of u+v is 2-4;

5

or a pharmaceutically acceptable salt thereof, provided that

when R6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

and further provided that

5

10

15

when Y is -NR6- and R7 is -NR6R6, -N(R6)3  $^{+}$ , or -NR6(OR6), then g = 2-6;

when M is -O- and R7 is -OR6, then p = 1-4;

when Y is -NR6-, then k = 2-4;

when Y is -O- and M or W is -O-, then k = 1-4

when W is not a bond with Het bonded through a nitrogen atom, then q=2-4 and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or -NR<sub>6</sub>-, then k=2-4.

9. A pharmaceutical composition which comprises a compound of formula 1 having the structure

$$G_1$$
 $R_1$ 
 $Z$ 
 $C \equiv N$ 
 $C \equiv N$ 

wherein:

20 X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono- di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms,


10

15

20

25

30



154 -

halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkenoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboxyalkyl of 2-7 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, mercapto, and benzoylamino;

Z is -NH-, -O-, -S-, or -NR-;

R is alkyl of 1-6 carbon atoms, or carboalkyl \$\sqrt{2-7}\$ carbon atoms;

G<sub>1</sub>, G<sub>2</sub>, R<sub>1</sub>, and R<sub>4</sub> are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6/carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of/4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms. alkylthio of 1-6 carbon /atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-b carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, M-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-Nalkenylamino of 4/to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,

$$R_{7}\text{-}(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{k}\text{-}Y - R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{k}\text{-}Y - (C(R_{6})_{2})_{p}$$

 $R_7$ -(C(R<sub>6</sub>)<sub>2</sub>)<sub>q</sub>-Y- ,  $R_7$ -(C(R<sub>6</sub>)<sub>2</sub>)<sub>p</sub>-M-(C(R<sub>6</sub>)<sub>2</sub>)<sub>k</sub>-Y- , or Het-( $\rlap/C$ (R<sub>6</sub>)<sub>2</sub>)<sub>q</sub>-W-(C(R<sub>6</sub>)<sub>2</sub>)<sub>k</sub>-Ywith the proviso that either G<sub>1</sub> or G<sub>2</sub> or both G<sub>1</sub>/and G<sub>2</sub> must be a radical selected from the group

$$(C(R_6)_2)_p$$
 $N-(C(R_6)_2)_k-Y R_8R_9-CH-M-(C(R_6)_2)_k-Y (C(R_6)_2)_p$ 
 $R_7-(C(R_6)_2)_p$ 
 $R_7-(C(R_6)_2)_p$ 
 $R_7-(C(R_6)_2)_p$ 
 $R_7-(C(R_6)_2)_p$ 
 $R_7-(C(R_6)_2)_p$ 
 $R_7-(C(R_6)_2)_p$ 
 $R_7-(C(R_6)_2)_p$ 

 $\mathsf{R'}_7 \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_g \text{-} \mathsf{Y} \text{-} \text{,} \quad \mathsf{R}_7 \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_p \text{-} \mathsf{M} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_k \text{-} \mathsf{Y} \text{-} \text{/} \text{,} \quad \mathsf{Het} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_q \text{-} \mathsf{W} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_k \text{-} \mathsf{Y} \text{-} \text{/} \text{,} \quad \mathsf{Het} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_q \text{-} \mathsf{W} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_k \text{-} \mathsf{Y} \text{-} \text{/} \text{,} \quad \mathsf{Het} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_q \text{-} \mathsf{W} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_k \text{-} \mathsf{Y} \text{-} \mathsf{/} \text{,} \quad \mathsf{Het} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_q \text{-} \mathsf{W} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_k \text{-} \mathsf{Y} \text{-} \mathsf{/} \text{,} \quad \mathsf{Het} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_q \text{-} \mathsf{W} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_q \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_q \text{-} \mathsf{W} \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_q \text{-} (\mathsf{C}(\mathsf{R}_6)_2)_$ 

R<sub>2</sub>-N-or

Y is a divalent radical selected from the group consisting of

$$-(CH_2)_a$$
 ,  $-O$  , and  $-N$ 

 $R_7$  is  $-NR_6R_6$ , -J,  $-OR_6$ ,  $-N(R_6)_3$ ,  $\phi r$   $-NR_6(OR_6)$ ;

R'7 is  $-NR_6(OR_6)$ ,  $-N(R_6)_3$  alken bxy of 1-6 carbon atoms, alkynoxy of 1-6 carbon atoms, N-alkyl-N-alkenylamino of A to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, N-alkyl-N-alkynylamino of 4 to 12 carbon atoms, N-alkenyl-Nalkynylamino of 4 to 12 carbon atoms, or N,N-dialkynylamino of 6-12 carbon atoms with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;


M is  $>NR_6$ ,  $-O_7$ ,  $>N_7$  ( $C(R_6)_2$ )  $NR_6R_6$ , or  $>N_7$  ( $C(R_6)_2$ )  $NR_6R_6$ 

20 W is  $>NR_6$ , -O- or is a bond

5

10

10



156 -

Het is a heterocycle selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane,


(OCH<sub>2</sub>CH<sub>2</sub>O)<sub>r</sub>

tetrahydropyran, and

wherein the heterocycle is optionally mono- or di-substituted on carbon or nitrogen with  $R_6$ , optionally mono- or di-substituted on carbon with hydroxy,  $-N(R_6)_2$ , or  $-OR_6$ , optionally mono or di-substituted on carbon with the mono-valent radicals  $-(C(R_6)_2)_SOR_6$  or  $-(C(R_6)_2)_SN(R_6)_2$ , or optionally mono or di-substituted on a saturated carbon with divalent radicals -O- or  $-O(C(R_6)_2)_SO$ -;

R6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;

25 R<sub>2</sub>, is selected from the group consisting of





$$R_5$$
 $R_5$ 
 $R_5$ 

R3 is independently hydrogen, alkyl of 1/6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2/7 carbon atoms,

$$R_{7}\text{-}(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r}\text{-}$$

$$(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r}\text{-}$$

$$(C(R_{6})_{2})_{p} - N - (C(R_{6})_{2})_{r}\text{-}$$

$$R_{7}\text{-}(C(R_{6})_{2})_{p}\text{-}M - (C(R_{6})_{2})_{r}\text{-}$$

$$R_{8}R_{9}\text{-}CH\text{-}M - (C(R_{6})_{2})_{r}\text{-} - \text{, or Het-}(C(R_{6})_{2})_{q}\text{-}W\text{-}(C(R_{6})_{2})_{r}\text{-} ;$$

with the proviso that at least one of the R3 groups is selected from the group

$$R_{7}-(C(R_{6})_{2})_{p}-N \qquad N-(C(R_{6})_{2})_{r}-1 \\ (C(R_{6})_{2})_{p} \qquad (C(R_{6})_{2})_{p}-1 \\ R'_{7}-(C(R_{6})_{2})_{s}- \qquad R_{7}-(C(R_{6})_{2})_{p}-1 \\ R_{8}R_{9}-CH-M-(C(R_{6})_{2})_{r}- \qquad , \text{ or } Het-(C(R_{6})_{2})_{q}-W-(C(R_{6})_{2})_{r}- \qquad ;$$

R5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

$$R_{7}-(C(R_{6})_{2})_{p}-N \qquad N-(C(R_{6})_{2})_{r}-N \\ (C(R_{6})_{2})_{p}-N-(C(R_{6})_{2})_{r}-N \\ R_{7}-(C(R_{6})_{2})_{s}-R_{7}-(C(R_{6})_{2})_{p}-M-(C(R_{6})_{2})_{r}-N \\ R_{8}R_{9}-CH-M-(C(R_{6})_{2})_{r}-N \\ N-(C(R_{6})_{2})_{p}-M-(C(R_{6})_{2})_{r}-N \\ N-(C(R_{6})_{2})_{p}-M-(C(R_{6})_{2})_{p}-N \\ N-(C(R_{6})_{2})_{p}-N \\ N-(C(R_{6})_{$$

R<sub>8</sub>, and R<sub>9</sub> are each, independently,  $-(C(R_6)_2)_rNR_6R_6$ , or  $-(C(R_6)_2)_rOR_6$ ;

J is independently hydrogen, chlorine, fluorine, or bromine; Q is alkyl of 1-6 carbon atoms or hydrogen;

$$a = 0 \text{ or } 1;$$

$$g = 1-6;$$

15 
$$k = 0-4$$
;

$$p = 2-4$$
;


$$q=0-4;$$

$$r = 1-4$$
;

$$s = 1-6$$
;

u = 0-4 and v = 0-4, wherein the sum of u+v is 2-4;

5



or a pharmaceutically acceptable salt thereof, provided that

when R6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

and further provided that

5

10

when Y is -NR6- and R7 is -NR6R6 -N(R6)3 , or -NR6(OR6), then g = 2-6;

when M is -O- and R7 is -OR6, then p = 1-4;

when Y is -NR6-, then k = 2-4/2

when Y is -O- and M or W is  $\sqrt{2}$ , then k = 1-4

when W is not a bond with Het bonded through a nitrogen atom, then q = 2-4 and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or -NR<sub>6</sub>-, then k = 2-4.